Cheng Will Ho-Gi, Mi Yuqi, Dong Weinan, Tse Emily Tsui-Yee, Wong Carlos King-Ho, Bedford Laura Elizabeth, Lam Cindy Lo-Kuen
Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Department of Family Medicine, The University of Hong Kong Shenzhen Hospital, Shenzhen 518009, China.
Diagnostics (Basel). 2023 Mar 29;13(7):1294. doi: 10.3390/diagnostics13071294.
Early detection of pre-diabetes (pre-DM) can prevent DM and related complications. This review examined studies on non-laboratory-based pre-DM risk prediction tools to identify important predictors and evaluate their performance. PubMed, Embase, MEDLINE, CINAHL were searched in February 2023. Studies that developed tools with: (1) pre-DM as a prediction outcome, (2) fasting/post-prandial blood glucose/HbA1c as outcome measures, and (3) non-laboratory predictors only were included. The studies' quality was assessed using the CASP Clinical Prediction Rule Checklist. Data on pre-DM definitions, predictors, validation methods, performances of the tools were extracted for narrative synthesis. A total of 6398 titles were identified and screened. Twenty-four studies were included with satisfactory quality. Eight studies (33.3%) developed pre-DM risk tools and sixteen studies (66.7%) focused on pre-DM and DM risks. Age, family history of DM, diagnosed hypertension and obesity measured by BMI and/or WC were the most common non-laboratory predictors. Existing tools showed satisfactory internal discrimination (AUROC: 0.68-0.82), sensitivity (0.60-0.89), and specificity (0.50-0.74). Only twelve studies (50.0%) had validated their tools externally, with a variance in the external discrimination (AUROC: 0.31-0.79) and sensitivity (0.31-0.92). Most non-laboratory-based risk tools for pre-DM detection showed satisfactory performance in their study populations. The generalisability of these tools was unclear since most lacked external validation.
早期发现糖尿病前期(pre-DM)可预防糖尿病(DM)及其相关并发症。本综述对基于非实验室的糖尿病前期风险预测工具的研究进行了考察,以确定重要预测因素并评估其性能。于2023年2月检索了PubMed、Embase、MEDLINE、CINAHL数据库。纳入的研究需满足以下条件:(1)以糖尿病前期作为预测结果;(2)以空腹/餐后血糖/HbA1c作为结局指标;(3)仅包含非实验室预测因素。使用CASP临床预测规则清单对研究质量进行评估。提取有关糖尿病前期定义、预测因素、验证方法及工具性能的数据进行叙述性综合分析。共识别并筛选出6398篇文献标题。纳入了24项质量令人满意的研究。8项研究(33.3%)开发了糖尿病前期风险工具,16项研究(66.7%)聚焦于糖尿病前期和糖尿病风险。年龄、糖尿病家族史、确诊的高血压以及通过BMI和/或腰围衡量的肥胖是最常见的非实验室预测因素。现有工具显示出令人满意的内部区分度(AUROC:0.68 - 0.82)、灵敏度(0.60 - 0.89)和特异度(0.50 - 0.74)。仅有12项研究(50.0%)对其工具进行了外部验证,外部区分度(AUROC:0.31 - 0.79)和灵敏度(0.31 - 0.92)存在差异。大多数基于非实验室的糖尿病前期检测风险工具在其研究人群中表现出令人满意的性能。由于大多数工具缺乏外部验证,其可推广性尚不清楚。